Clinical Trials

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT04852887 2026-04-15

DEBRA

Phase 3 Recruiting

1,670 enrolled

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

2,000 enrolled

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Phase 4 Completed

29 enrolled

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Phase 4 Completed

39 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04569747 2026-04-02

ADEPT

393 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07499999 2026-03-30

BabyTEARS

140 enrolled

Breast Neoplasms, Carcinoma, Ductal

NCT05659563 2026-03-19

EMPRESS

92 enrolled 14 charts

Breast Neoplasms

NCT00893061 2026-03-17

MNEMOSYNE

Phase 3 Completed

44 enrolled

Breast Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

400 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06982313 2026-03-11

Babytam long

Completed

1,545 enrolled

BreastOther neoplasm

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Precancerous Conditions

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

1,156 enrolled

Breast Carcinoma In Situ

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Phase EARLY_PHASE1 Recruiting

Triple Negative Breast Neoplasms

NCT06942039 2026-02-27

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

15 enrolled

CNS

Medulloblastoma, Neuroblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

354 enrolled

Breast Neoplasms

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

41 enrolled 9 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

19 enrolled 10 charts

Breast Neoplasms

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Phase 2 Terminated

65 enrolled

Phase 2 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

1,903 enrolled

Breast Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

49 enrolled 14 charts